Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

12.79USD
22 May 2017
Change (% chg)

$-0.12 (-0.93%)
Prev Close
$12.91
Open
$12.91
Day's High
$13.00
Day's Low
$12.51
Volume
1,900,473
Avg. Vol
1,349,855
52-wk High
$15.20
52-wk Low
$7.70

Select another date:

Thu, May 18 2017

BRIEF-Halozyme Therapeutics prices public offering of common stock

* Halozyme Therapeutics prices public offering of common stock

BRIEF-Halozyme Therapeutics announces public offering of common stock

* Halozyme Therapeutics announces public offering of common stock

BRIEF-Halozyme's PEGPH20 increases immune response, effectiveness of immunotherapies in preclinical cancer models

* Halozyme's PEGPH20 increases immune response and effectiveness of immunotherapies in preclinical cancer models

BRIEF-Halozyme provides update on SWOG Collaborative Group clinical study

* Halozyme provides update on swog collaborative group clinical study

BRIEF-Halozyme Therapeutics Q4 loss per share $0.21

* Says for 2017, company reiterated and updated cash portions of its financial guidance

BRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing

* First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing Source text: [http://bit.ly/2kkBxab] Further company coverage:

BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln

* Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses

BRIEF-Halozyme sees FY 2017 revenue $115 mln to $130 mln

* Halozyme provides program updates, 2017 financial guidance at 35th annual JP Morgan healthcare conference

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Select another date:

More From Around the Web